Stem Cell-Based Technology for Personalized Medicine Solutions
A special issue of Bioengineering (ISSN 2306-5354). This special issue belongs to the section "Regenerative Engineering".
Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 8525
Special Issue Editors
Interests: stem cell differentiation; organoids generation; tissue bioengineering; cell transplantation
Special Issues, Collections and Topics in MDPI journals
Interests: kidney transplantation; robotic surgery; surgical oncology; immunology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Personalized stem cell-based therapy represents the potential future for the treatment of degenerative diseases that cause the loss of organ function. Through the application of bioengineering technologies, it is possible to recreate in vitro cell products that resemble the real organ, called organoids. This promising technology has already introduced several bioengineered tissues to the clinical trial level, and more can be done to cover the demand for different organs that can be subject to functional failure. However, this very advanced field still faces challenges in making these organoids fully functional and in protecting them from the host immune system to prevent rejection after transplantation. In this Special Issue of Bioengineering on Stem Cell-Based Technology for Personalized Medicine Solutions, we will present what the latest research has to offer in regenerative medicine, stem cell technology, and in the bioengineering of tissues and materials, with experts from all over the world presenting their contributions to this very important scientific field.
Dr. Giuseppe Pettinato
Dr. Giuseppe Ietto
Dr. Xuejun Wen
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- stem cells
- organoids
- differentiation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.